Latest Breaking News On - Mismatch repair deficient cancer - Page 3 : comparemela.com

Merck (MRK) Announces KEYNOTE-991 Trial Evaluating KEYTRUDA Plus Enzalutamide and Androgen Deprivation Therapy

Merck (MRK) Announces KEYNOTE-991 Trial Evaluating KEYTRUDA Plus Enzalutamide and Androgen Deprivation Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJulie cunninghamScot ebbinghausChrissy trankPeter dannenbaumDamini chokshiMerck research laboratoriesData monitoring committeeStatement of merck co incOrion corporation forMerck co incExchange commissionWall streetMerck researchOrion corporationProstate cancer working group modified

Merck s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Merck s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPeter dannenbaumJohn infantiDamini chokshiMelissa moodyEliav barrMerck research laboratoriesStatement of merck co incExchange commissionMerck co incJapan ministry of healthWall streetMerck researchKyle tattleRepresentative directorNeck squamous cell cancer

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that its first self-developed innovative PD-1 inhibitor HANSIZHUANG (generic name:.

United statesKalbe genexine biologicsLi jinZhang wenjieQin shukuiWray mcdermottPrnewswire shanghai henlius biotech incTongji universityTumor centerEuropean unionNational medical products administrationDepartment of oncologyChinese society of clinical oncologyHenlius biotechMicrosatellite instability highExecutive director

New Research for KEYTRUDA® at Society for Melanoma Research 2021 Congress Reinforces Merck s Commitment to Patients With Melanoma Across Stages of Disease

KEYTRUDA Continued To Improve Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB or IIC Melanoma at 2 nd Interim Analysis of Phase 3 KEYNOTE-716 Trial Exploratory 7-Year Follow-Up Data for KEYTRUDA in Advanced Melanoma Showed 38% of Patients Treated With KEYTRUDA Were Alive at 7 Years Merck known as MSD outside the United States and Canada, today announced new data .

United statesPeter dannenbaumMelissa moodyRoy baynesMerck research laboratoriesStatement of merck co incExchange commissionMerck co incSociety for melanoma researchAdjuvant therapyPatients with resected stageInterim analysisYear follow up dataAdvanced melanoma showedPatients treated withMelanoma research

European Commission Approves Merck s KEYTRUDA® Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer

KEYTRUDA Is Now Approved in Combination With Chemotherapy as First-Line Treatment for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 and Who Have Not Received Prior Chemotherapy for Metastatic Disease KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From .

United statesVicki goodmanPeter dannenbaumJavier cortMelissa moodyQuironsalud groupMerck research laboratoriesEuropean commissionStatement of merck co incExchange commissionMerck co incEuropean unionInternational breast cancer centerNow approvedFirst line treatmentPatients with locally recurrent unresectable